Risk of lymphoid malignancy associated with cancer predisposition genes - Takeaways - MDSpire

Risk of lymphoid malignancy associated with cancer predisposition genes

  • By

  • Nicholas J. Boddicker

  • Raphael Mwangi

  • Dennis P. Robinson

  • Cristine Allmer

  • Allison C. Rosenthal

  • Thomas M. Habermann

  • Andrew L. Feldman

  • Lisa M. Rimsza

  • Rebecca L. King

  • Melissa C. Larson

  • Bri J. Negaard

  • Aaron D. Norman

  • Nikhil Rajkumar

  • Stephen M. Ansell

  • Angela Dispenzieri

  • David L. Murray

  • Vincent Rajkumar

  • Shaji Kumar

  • Jithma P. Abeykoon

  • Grzegorz S. Nowakowski

  • Thomas E. Witzig

  • Anne J. Novak

  • Susan L. Slager

  • Celine M. Vachon

  • James R. Cerhan

  • April 19, 2025

  • 0 min

Share

  • 1

    Lymphoid malignancies (LM) encompass over 100 subtypes, with an estimated 125,110 new cases in the U.S. in 2023.

  • 2

    Family history is a significant risk factor for LM, with specific subtypes showing a >4-fold risk increase for chronic lymphocytic leukemia and others.

  • 3

    Genome-wide association studies have identified susceptibility variants for several LM subtypes, indicating a genetic component to their risk.

  • 4

    Pathogenic variants in cancer predisposition genes, such as BRCA1 and TP53, may increase the risk of lymphoid malignancies.

  • 5

    Further research is needed to clarify the relationship between pathogenic variants and the risk of lymphoid malignancies and their subtypes.

Original Source(s)

Risk of lymphoid malignancy associated with cancer predisposition genes

  • by Nicholas J. Boddicker, Raphael Mwangi, Dennis P. Robinson, Cristine Allmer, Allison C. Rosenthal, Thomas M. Habermann, Andrew L. Feldman, Lisa M. Rimsza, Rebecca L. King, Melissa C. Larson, Bri J. Negaard, Aaron D. Norman, Nikhil Rajkumar, Stephen M. Ansell, Angela Dispenzieri, David L. Murray, Vincent Rajkumar, Shaji Kumar, Jithma P. Abeykoon, Grzegorz S. Nowakowski, Thomas E. Witzig, Anne J. Novak, Susan L. Slager, Celine M. Vachon, James R. Cerhan

  • April 19, 2025

Related Content

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”